Skip to main content

Amneal Pharmaceuticals, Inc.

corporate_fare Company Profile

Amneal Pharmaceuticals, Inc.

AMRX·NASDAQ·Life Sciences·CIK 0001723128

Amneal Pharmaceuticals, Inc. is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. The company operates through three segments. Its Affordable Medicines segment includes retail generics, injectables, and biosimilars. The Specialty segment offers a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, Amneal Pharmaceuticals is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. The company operates principally in the United States, India, and Ireland. Amneal Pharmaceuticals is a holding company. Immediately prior to a reorganization on November 7, 2023, the company held 50.4% of the common units of Amneal Pharmaceuticals, LLC, while the Amneal Group held the remaining 49.6%. On November 7, 2023, the company reorganized its corporate structure, converting to a traditional C-corporation structure. Effective with this reorganization, Amneal Pharmaceuticals holds 100% of the Amneal Common Units and continues to consolidate the financial statements of Amneal Pharmaceuticals, LLC and its subsidiaries. Prior to March 2023, the company had a minority economic interest in Amneal Pharmaceuticals, LLC but was its sole managing member, controlling its business decisions and management.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 40 items for AMRX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Amneal Wins FDA Approval for Romidepsin Injection, Securing 180-Day Exclusivity
  • Amneal Reports Strong Q1 Earnings, Announces Major Kashiv BioSciences Acquisition
  • Amneal Pharmaceuticals Files Proxy Materials for Kashiv BioSciences Acquisition, Reports Strong Preliminary Q1 Results
  • Amneal to Acquire Kashiv BioSciences, Reports Strong Q1 Results & Raises Full-Year Guidance
  • Amneal to Acquire Kashiv BioSciences for $750M Upfront, Unveils Strong Q1 Preliminary Results

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.02B
Net Income
$72.06M
Diluted EPS
$0.22
Op. Cash Flow
$339.99M
Free Cash Flow
$269.93M
Gross Profit
$1.11B
Operating Income
$394.1M
Cash & Equivalents
$282.03M
Total Debt
$2.57B
Debt / Equity
-36.33×
Net Margin
2.4%
Shares Outstanding
313.37M sh
Source: 10-K · filed 2026-02-27 · accession 0001723128-26-000011
$21.78 +3.15% today
52-week range · as of 2026-11-09 $11.29 – $21.78
Market cap
$7.36B
Volume
1.7M (0.4× avg)
3-mo avg 3.7M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AMRX - Filings & News (Page 2)

AMRX
Jun 04, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $12.99
Real-time Price: $21.78 info
Change: +$8.80 (+68%) info
Market Cap: $7.358B info
AMRX
May 07, 2026, 4:22 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $13.72
Real-time Price: $21.78 info
Change: +$8.06 (+59%) info
Market Cap: $7.358B info
AMRX
Apr 22, 2026, 5:00 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $12.82
Real-time Price: $21.78 info
Change: +$8.96 (+70%) info
Market Cap: $7.358B info
AMRX
Apr 22, 2026, 4:28 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $12.82
Real-time Price: $21.78 info
Change: +$8.96 (+70%) info
Market Cap: $7.358B info
AMRX
Apr 22, 2026, 4:23 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $12.82
Real-time Price: $21.78 info
Change: +$8.96 (+70%) info
Market Cap: $7.358B info
AMRX
Apr 22, 2026, 6:24 AM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $13.41
Real-time Price: $21.78 info
Change: +$8.37 (+62%) info
Market Cap: $7.358B info
AMRX
Apr 22, 2026, 6:22 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.41
Real-time Price: $21.78 info
Change: +$8.37 (+62%) info
Market Cap: $7.358B info
AMRX
Apr 22, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $13.30
Real-time Price: $21.78 info
Change: +$8.48 (+64%) info
Market Cap: $7.358B info
AMRX
Apr 20, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $13.94
Real-time Price: $21.78 info
Change: +$7.84 (+56%) info
Market Cap: $7.358B info
AMRX
Mar 26, 2026, 6:23 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $12.06
Real-time Price: $21.78 info
Change: +$9.72 (+81%) info
Market Cap: $7.358B info
AMRX
Mar 25, 2026, 4:15 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $12.26
Real-time Price: $21.78 info
Change: +$9.52 (+78%) info
Market Cap: $7.358B info
AMRX
Feb 27, 2026, 4:19 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $14.08
Real-time Price: $21.78 info
Change: +$7.70 (+55%) info
Market Cap: $7.358B info
AMRX
Feb 27, 2026, 6:16 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.49
Real-time Price: $21.78 info
Change: +$7.29 (+50%) info
Market Cap: $7.358B info
AMRX
Feb 27, 2026, 6:02 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $14.49
Real-time Price: $21.78 info
Change: +$7.29 (+50%) info
Market Cap: $7.358B info
AMRX
Feb 27, 2026, 6:01 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $14.49
Real-time Price: $21.78 info
Change: +$7.29 (+50%) info
Market Cap: $7.358B info
AMRX
Feb 27, 2026, 6:00 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $14.49
Real-time Price: $21.78 info
Change: +$7.29 (+50%) info
Market Cap: $7.358B info
AMRX
Feb 27, 2026, 6:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $14.49
Real-time Price: $21.78 info
Change: +$7.29 (+50%) info
Market Cap: $7.358B info
AMRX
Feb 02, 2026, 6:36 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.31
Real-time Price: $21.78 info
Change: +$7.47 (+52%) info
Market Cap: $7.358B info
AMRX
Jan 28, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.97
Real-time Price: $21.78 info
Change: +$7.81 (+56%) info
Market Cap: $7.358B info
AMRX
Jan 13, 2026, 7:44 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.09
Real-time Price: $21.78 info
Change: +$8.69 (+66%) info
Market Cap: $7.358B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets